Pila Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021
For the full year, sales was SEK 0.719 million. Net loss was SEK 17.21 million compared to SEK 6.98 million a year ago. Basic loss per share from continuing operations was SEK 1.32 compared to SEK 0.7 a year ago. Diluted loss per share from continuing operations was SEK 1.32 compared to SEK 0.7 a year ago.